Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma

doi:10.4254/wjh.v14.i3.623

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3657)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-6) series.

Item

Count

PDF

190

WORD

HTML

1474

Figures (1-3)

255

Tables (1-6)

225

Sum=2238

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

316

Download

1103

Sum=1419

Mar 27, 2022 (publication date) through Nov 29, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Mar 27, 2022; 14(3): 623-633
Published online Mar 27, 2022. doi: 10.4254/wjh.v14.i3.623

Full Size Figure Download Figure

Figure 1 Serum fibroblast growth factor 19 levels in the control, cirrhosis, and hepatocellular carcinoma groups. FGF-19: Fibroblast growth factor 19; HCC: Hepatocellular carcinoma.

Citation: Mohamed GA, Nashaat EH, Fawzy HM, ElGhandour AM. Assessment of fibroblast growth factor 19 as a non-invasive serum marker for hepatocellular carcinoma. World J Hepatol 2022; 14(3): 623-633
URL: https://www.wjgnet.com/1948-5182/full/v14/i3/623.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i3.623